Effect of prostaglandin E1 on deposition of autologous labelled platelets onto human atherosclerotic lesions in vivo.
The effects of infusions of prostaglandin E1 (PGE1) on platelet deposition at atherosclerotic sites in vivo in man have been examined. Thirteen patients with atherosclerotic vascular disease received intravenous PGE1 25 mg/kg/min for 6 hours daily for 5 days. Prostaglandin E1 had no effect on platelet uptake at atherosclerotic sites but prolonged platelet half-life significantly (P less than 0.001).
Sinzinger
H
H
Department of Nuclear Medicine, University of Vienna, Austria.
O'Grady
J
J
Fitscha
P
P
D000527:Alprostadil / Q000493:pharmacokinetics*; D001161:Arteriosclerosis / Q000378:metabolism / Q000473:pathology*; D001792:Blood Platelets / Q000187:drug effects / Q000502:physiology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
D000527:Alprostadil